AlphaQuest LLC Has $1.86 Million Stock Holdings in Boston Scientific Corporation $BSX

AlphaQuest LLC boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 122.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 19,454 shares of the medical equipment provider’s stock after buying an additional 10,710 shares during the quarter. AlphaQuest LLC’s holdings in Boston Scientific were worth $1,855,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter worth $26,000. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. United Community Bank grew its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the period. Colonial Trust Co SC grew its holdings in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares during the period. Finally, Bangor Savings Bank grew its holdings in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 12.7%

Shares of NYSE:BSX opened at $50.34 on Thursday. The company’s 50-day moving average price is $61.13 and its two-hundred day moving average price is $79.19. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a one year low of $50.04 and a one year high of $109.50. The stock has a market capitalization of $74.82 billion, a PE ratio of 21.06, a price-to-earnings-growth ratio of 1.06 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the firm posted $0.75 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Boston Scientific cut its 2026 growth outlook and signaled softer demand in WATCHMAN and urology, raising concerns that near-term revenue growth may underdeliver versus prior expectations. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Management also highlighted competitive pressure in electrophysiology and a more cautious near-term operating backdrop, which added to investor concerns and helped trigger the stock’s sharp decline. Boston Scientific (BSX) slides after management cuts 2026 growth outlook
• Neutral Sentiment: On the positive side, Boston Scientific still has an active product pipeline, and one recent device trial reported strong efficacy, which could support the longer-term growth story if commercial adoption follows. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Neutral Sentiment: The company also deployed capital into a large private-company stake, which may appeal to long-term strategic investors but is not the main driver of the stock’s move today. Boston Scientific Is Betting $1.5 Billion on a Massive Market — and Wall Street Is Paying Attention

Wall Street Analysts Forecast Growth

BSX has been the subject of several research analyst reports. Stifel Nicolaus set a $75.00 price target on shares of Boston Scientific in a report on Wednesday. Truist Financial reduced their target price on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research note on Thursday, April 23rd. Bank of America reduced their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research note on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.29.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 9,800 shares of company stock valued at $554,012 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.